Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Martin, Ullmann"'
Autor:
Peter Baker, Anna Zubrzycka-Sienkiewicz, Kamilla Klama, Martin Ullmann, Corinne Petit-Frere, Joëlle Monnet, Andras Illes
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objective To evaluate the efficacy, immunogenicity and safety of the proposed biosimilar MSB11456 versus European Union (EU)-approved tocilizumab reference product in patients with rheumatoid arthritis (RA) in a multicentre, randomised, double-blind,
Externí odkaz:
https://doaj.org/article/34072ee0ff6a4c5cb76c4a8cc3281afd
Autor:
Monika Tomaszewska-Kiecana, Anna Dryja, Martin Ullmann, Corinne Petit-Frere, Andras Illes, Christos Dagres, Joëlle Monnet
Publikováno v:
Expert Review of Clinical Immunology. 19:447-455
Autor:
Monika Tomaszewska-Kiecana, Martin Ullmann, Corinne Petit-Frere, Joëlle Monnet, Christos Dagres, Andras Illes
Publikováno v:
Expert Review of Clinical Immunology. 19:439-446
Autor:
Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Abstract MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerabilit
Externí odkaz:
https://doaj.org/article/7beea784365047a58e0ab0cad4fdf7c7
Autor:
Gregor P. Lotz, Karin Benstein, Karien Bloem, Harm Buddiger, Claudio Calonder, Stefanie Elm, Elena Fernandez, Joanne Goodman, Boris Gorovits, Joanna Grudzinska-Goebel, Melody Janssen, Vibha Jawa, Daniel Kramer, Linlin Luo, Mantas Malisauskas, Lydia Michaut, Martin Schäfer, Sebastian Spindeldreher, Martin Ullmann, Karin Nana Weldingh, Arno Kromminga, Veerle Snoeck
Publikováno v:
The AAPS Journal. 24
The determination of a tailored anti-drug antibody (ADA) testing strategy is based on the immunogenicity risk assessment to allow a correlation of ADAs with changes to pharmacokinetics, efficacy, and safety. The clinical impact of ADA formation refin
Autor:
Christian Schwabe, Andras Illes, Martin Ullmann, Vishal Ghori, Emmanuelle Vincent, Corinne Petit-Frere, Joelle Monnet, Anne Sophie Racault, Chris Wynne
Tocilizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody against the interleukin-6 receptor (IL-6 R). MSB11456 is a proposed tocilizumab biosimilar. To assess the pharmacokinetic and pharmacodynamic similarity of MSB11456 to both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5467200e265670149b1e8f673c90bc57
Autor:
V. Chyrok, Kim A. Papp, Jana Hercogová, Pantelis Vlachos, Martin Ullmann, Christopher J Edwards
Publikováno v:
British Journal of Dermatology. 182:316-326
Background MSB11022 is a proposed adalimumab biosimilar. Objectives To compare the efficacy, safety and immunogenicity of MSB11022 with reference adalimumab. Methods AURIEL-PsO was a double-blind randomized controlled equivalence trial, in which pati
Autor:
Armin Schueler, Michael Stahl, Christian Schwabe, Radmila Kanceva, Vishal Ghori, Janka Ryding, Chris Wynne, Emmanuelle Vincent, Martin Ullmann
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB1
Autor:
Martin Ullmann, Michael Stahl, Corinne Seng Yue, Vishal Ghori, Paul M. Griffin, Jason D. Lickliter, Radmila Kanceva, Eleanor Harrison-Moench, Emmanuelle Vincent, Armin Schueler
Publikováno v:
Clinical therapeutics. 42(8)
Purpose MSB11455 is a proposed biosimilar to the reference pegfilgrastim (Neulasta®). This pivotal equivalence study (NCT03251248) assessed the pharmacokinetic and pharmacodynamic equivalence of MSB11455 to the reference product. Methods This 2-way,
Autor:
Chris, Wynne, Christian, Schwabe, Emmanuelle, Vincent, Armin, Schueler, Janka, Ryding, Martin, Ullmann, Vishal, Ghori, Radmila, Kanceva, Michael, Stahl
Publikováno v:
Pharmacology Research & Perspectives
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB1